Navigation Links
Avantra Biosciences Offers Its Proprietary PATH® Slides for Sale

WOBURN, Mass., March 22, 2011 /PRNewswire/ -- Avantra Biosciences has announced they are selling their new and improved proprietary PATH® Protein Microarray Ultra-thin Nitrocellulose Slides. Additionally, Avantra is discussing the possibility of partnering with certain parties to expand the distribution network for the PATH slides.

The PATH Slide is the first protein microarray slide to provide the many benefits of nitrocellulose in a thin film that allows very low background fluorescence and excellent signal-to-noise ratio.

"Nitrocellulose has proven to be the protein-assay substrate of choice for decades. With this technology, researchers can use a wide variety of fluorescence probes to make protein assays easier, faster and more sensitive than ever before," said Brendan McKernan, President of Avantra Biosciences. "By delivering a high signal-to-noise ratio and low background fluorescence, we believe the PATH surface chemistry to be far superior to other commercially available protein-array surfaces."

Key Features:

  • Excellent stability and shelf life

  • Best in class sensitivity, accuracy, and reproducibility and dynamic range providing excellent spot morphology, retained protein conformation and functional activity.

  • Low background and increased dynamic range – proprietary ultra-thin nitrocellulose provides enhances signal-to-noise ratios

  • Standard slide format – adaptable to all commonly used slide format microarray readers

Ordering information
Phone: 877.395.7608
Fax: 617.892.7191

About Avantra Biosciences Corporation

Avantra Biosciences is a privately held diagnostics company that has pioneered next generation technology for protein biomarker analysis.  The PATH technology is integrated into the Avantra Q400 Biomarker Workstation.  Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) from their lab bench or clinical trial site.

Copyright © 2011 Avantra Biosciences Corporation. All rights reserved.

SOURCE Avantra Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
3. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
4. Swift Biosciences Presents Highly Sensitive, Highly Specific qPCR Mutation Detection Data at 18th International Molecular Medicine Tri-Conference
5. Martek Biosciences Inducted into Small Business Innovation Research (SBIR) Hall of Fame
6. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
7. YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
8. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
10. YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
11. Ardea Biosciences Prices Public Offering of Common Stock
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):